<!DOCTYPE html>
<html>
<head>
<meta http-equiv="Content-Type" content="application/xml; charset=UTF-8">
<title>input-fr</title>
</head>
<body><div id="lawcontent">
<div id="preface">
<!--531.80 --><p class="srnummer">531.80 </p>
<h1 class="erlasstitel botschafttitel">Ordonnance<br>sur le bureau de notification pour les médicaments vitaux à usage humain</h1>
<p class="erlassdatum man-space-before-3">du 28 mai 2025 (État le 1<sup>er</sup> juillet 2025)</p>
</div>
<div id="preamble"><div>
<p class="man-template-autor man-space-before-10">Le Conseil fédéral suisse,</p>
<p class="ingress man-space-before-3">vu l’art. 57, al. 1, de la loi du 17 juin 2016 sur l’approvisionnement du pays<sup><a href="#fn-d7e21" id="fnbck-d7e21">1</a></sup>,</p>
<p class="man-template-verb man-space-before-3 man-space-after-18">arrête:</p>
<div class="footnotes"><p id="fn-d7e21"><sup><a href="#fnbck-d7e21">1</a></sup><sup></sup> <a href="https://fedlex.data.admin.ch/eli/cc/2017/308" target="_blank">RS <b>531</b></a></p></div>
</div></div>
<main id="maintext"><section id="sec_1"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#sec_1">Section 1 Bureau de notification</a>
</h1>
<div class="collapseable"><article id="art_1"><a name="a1"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_1"><b>Art. 1</b></a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> Le domaine Produits thérapeutiques de l’organisation de l’approvisionnement économique du pays gère un bureau de notification pour garantir l’approvisionnement du pays en médicaments vitaux à usage humain.</p>
<p class="absatz man-space-before-4"><sup>2</sup> Sont réputés vitaux les médicaments à usage humain autorisés par l’Institut suisse des produits thérapeutiques:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">qui ne sont pas ou guère substituables; et</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">dont l’absence prolongée aurait de graves conséquences sanitaires.</dd>
</dl>
</div></article></div></section><section id="sec_2"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#sec_2">Section 2 Notification</a>
</h1>
<div class="collapseable">
<article id="art_2"><a name="a2"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_2"><b>Art. 2</b> Obligation de notifier</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> Les titulaires d’autorisations qui mettent sur le marché des médicaments à usage humain contenant un des principes actifs mentionnés en annexe doivent notifier au bureau de notification toute pénurie ou rupture de stock de médicaments vitaux à usage humain, prévisible ou imprévisible, qui durera vraisemblablement plus de quatorze jours.</p>
<p class="absatz man-space-before-4"><sup>2</sup> Ils doivent notifier le dosage concerné d’une forme galénique et à partir de quand il sera vraisemblablement de nouveau disponible à la livraison.</p>
<p class="absatz man-space-before-4"><sup>3</sup> Une pénurie ou une rupture de stock ne doit pas être notifiée si elle concerne seulement une taille d’emballage d’un dosage donné d’une forme galénique qu’on peut remplacer par une autre taille.</p>
<p class="absatz man-space-before-4"><sup>4</sup> Les notifications doivent être faites dans les cinq jours ouvrables à compter du moment où le titulaire de l’autorisation en a eu connaissance.</p>
</div></article><article id="art_3"><a name="a3"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_3"><b>Art. 3</b> Contenu et forme de la notification</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> Le titulaire de l’autorisation doit notamment notifier les informations suivantes:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">le nom, l’adresse et un interlocuteur;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">le numéro d’autorisation et le code article international du médicament à usage humain;</dd>
<dt class="man-space-before-4">c. </dt>
<dd class="man-space-before-4">la désignation exacte du médicament à usage humain, y compris le principe actif, la forme galénique, le dosage et la taille de l’emballage;</dd>
<dt class="man-space-before-4">d. </dt>
<dd class="man-space-before-4">les faits, y compris leurs causes, les services concernés en Suisse et à l’étranger, le niveau actuel des stocks et les ventes passées et escomptées;</dd>
<dt class="man-space-before-4">e. </dt>
<dd class="man-space-before-4">l’existence de médicaments équivalents en Suisse ou à l’étranger;</dd>
<dt class="man-space-before-4">f. </dt>
<dd class="man-space-before-4">le début, la durée et l’ampleur de la pénurie ou de la rupture de stock;</dd>
<dt class="man-space-before-4">g </dt>
<dd class="man-space-before-4">les mesures prises ou prévues en lien avec la pénurie ou la rupture de stock.</dd>
</dl>
<p class="absatz man-space-before-4"><sup>2</sup> La notification doit être faite par l’intermédiaire du système d’information du bureau de notification (Plateforme des produits thérapeutiques). Si, pour des raisons techniques, l’utilisation de la Plateforme des produits thérapeutiques est impossible, les informations doivent être transmises par un autre moyen électronique ou par voie postale.</p>
</div></article><article id="art_4"><a name="a4"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_4"><b>Art. 4</b> Signalement de pénuries ou de ruptures de stock</a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4">Les cantons, les hôpitaux, les médecins, les pharmaciens et les grossistes peuvent signaler au bureau de notification le risque d’une pénurie ou d’une rupture de stock.</p></div></article>
</div></section><section id="sec_3"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#sec_3">Section 3 Information et recommandations</a>
</h1>
<div class="collapseable">
<article id="art_5"><a name="a5"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_5"><b>Art. 5</b> Information des autorités sanitaires et des fournisseurs de prestations</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> Le bureau de notification examine les notifications et informe les autorités sanitaires des cantons et de la Confédération ainsi que les fournisseurs de prestations suivants des pénuries et des ruptures de stock:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">les médecins;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">les pharmaciens;</dd>
<dt class="man-space-before-4">c. </dt>
<dd class="man-space-before-4">les sages-femmes;</dd>
<dt class="man-space-before-4">d. </dt>
<dd class="man-space-before-4">les personnes prodiguant des soins sur prescription ou sur mandat médical ainsi que les organisations qui les emploient;</dd>
<dt class="man-space-before-4">e. </dt>
<dd class="man-space-before-4">les hôpitaux;</dd>
<dt class="man-space-before-4">f. </dt>
<dd class="man-space-before-4">les maisons de naissance;</dd>
<dt class="man-space-before-4">g. </dt>
<dd class="man-space-before-4">les établissements médico-sociaux;</dd>
<dt class="man-space-before-4">h. </dt>
<dd class="man-space-before-4">les institutions de soins ambulatoires dispensés par des médecins.</dd>
</dl>
<p class="absatz man-space-before-4"><sup>2</sup> Le domaine Produits thérapeutiques informe les autorités sanitaires des cantons et de la Confédération et les fournisseurs de prestations concernés sur d’autres principes actifs et sur des possibilités de substitution.</p>
<p class="absatz man-space-before-4"><sup>3</sup> Lors d’un signalement au sens de l’art. 4, le titulaire de l’autorisation doit confirmer la pénurie ou la rupture de stock avant que le bureau de notification transmette l’information.</p>
</div></article><article id="art_6"><a name="a6"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_6"><b>Art. 6</b> Recommandations</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4">Si un médicament à usage humain est soumis à l’obligation de notifier, le domaine Produits thérapeutiques émet des recommandations afin:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">de limiter l’usage de médicaments à usage humain à certaines indications ou à certains groupes de patients;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">d’importer des médicaments à usage humain non autorisés en Suisse, mais provenant d’un pays ayant institué un contrôle des médicaments équivalent;</dd>
<dt class="man-space-before-4">c. </dt>
<dd class="man-space-before-4">d’approuver des demandes faites par des titulaires d’autorisations en vue de la mise sur le marché, pour une durée limitée, de médicaments à usage humain identiques dans un emballage étranger.</dd>
</dl>
</div></article>
</div></section><section id="sec_4"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#sec_4">Section 4 Protection des données</a>
</h1>
<div class="collapseable">
<article id="art_7"><a name="a7"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_7"><b>Art. 7</b> Accès à la Plateforme des produits thérapeutiques</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4">Ont accès à la Plateforme des produits thérapeutiques:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">le personnel du bureau de notification;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">le conseiller à la protection des données de l’Office fédéral pour l’approvisionnement économique du pays, pour assumer ses fonctions de contrôle;</dd>
<dt class="man-space-before-4">c. </dt>
<dd class="man-space-before-4">les personnes chargées de l’exploitation et de la maintenance du système.</dd>
</dl>
</div></article><article id="art_8"><a name="a8"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_8"><b>Art. 8</b> Principes régissant la communication des données</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4" msg:wcstyle02-4="loose pPr/keepLines" xmlns:msg="urn:com:c-moria:legi4ch:xslt:message"><sup>1</sup> Les données provenant de la Plateforme des produits thérapeutiques peuvent uniquement être communiquées:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">à l’autorité sanitaire d’un canton ou de la Confédération: pour l’accomplissement de son mandat légal;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">à des tiers, s’ils utilisent ces données exclusivement à des fins scientifiques.</dd>
</dl>
<p class="absatz man-space-before-4"><sup>2</sup> Avant toute communication au sens de l’al. 1, let. b, le bureau de notification anonymise les données et veille à ce qu’elles ne permettent pas de remonter à un secret d’affaires ou de fabrication.</p>
<p class="absatz man-space-before-4"><sup>3</sup> Les destinataires des données prennent des mesures organisationnelles et techniques permettant d’assurer que l’utilisation des données se limite au but indiqué. La communication des données n’est licite qu’avec l’accord du bureau de notification.</p>
</div></article><article id="art_9"><a name="a9"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_9"><b>Art. 9</b> Communication de données à l’Institut suisse des produits thérapeutiques</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4">Le bureau de notification donne au personnel de l’Institut suisse des produits thérapeutiques un accès en ligne aux données suivantes, si celui-ci en a besoin pour traiter des demandes en vertu de l’art. 9<i>b</i>, al. 2, de la loi du 15 décembre 2000 sur les produits thérapeutiques (LPTh)<sup><a href="#fn-d7e279" id="fnbck-d7e279">2</a></sup>:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">les données relatives aux pénuries et aux ruptures de stock de médicaments à usage humain soumis à l’obligation de notifier;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">les évaluations et les recommandations du domaine Produits thérapeutiques sur la situation en matière d’approvisionnement;</dd>
<dt class="man-space-before-4">c. </dt>
<dd class="man-space-before-4">les informations concernant les possibilités de substitution.</dd>
</dl>
<div class="footnotes"><p id="fn-d7e279"><sup><a href="#fnbck-d7e279">2</a></sup><sup></sup> <a href="https://fedlex.data.admin.ch/eli/cc/2001/422" target="_blank">RS <b>812.21</b></a></p></div>
</div></article><article id="art_10"><a name="a10"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_10"><b>Art. 10</b> Communication de données à Helvecura</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4">Le bureau de notification donne au personnel de l’organisation d’entraide des détenteurs de réserves obligatoires de médicaments (Helvecura) un accès en ligne aux données suivantes, si celle-ci en a besoin pour exécuter les tâches qui lui sont déléguées en lien avec le stockage obligatoire:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">les données relatives aux livraisons et aux ventes des médicaments à usage humain répertoriés sur la Plateforme des produits thérapeutiques;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">les coordonnées de l’interlocuteur;</dd>
<dt class="man-space-before-4">c. </dt>
<dd class="man-space-before-4">les données statistiques.</dd>
</dl>
</div></article><article id="art_11"><a name="a11"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_11"><b>Art. 11</b> Communication de données par Refdata et Helvecura</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4" msg:wcstyle02-4="loose pPr/keepLines" xmlns:msg="urn:com:c-moria:legi4ch:xslt:message"><sup>1</sup> Les services suivants doivent donner au bureau de notification un accès en ligne aux données ci-après:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">l’institution visée à l’art. 67, al. 3, LPTh<sup><a href="#fn-d7e345" id="fnbck-d7e345">3</a></sup> (Refdata): toutes les données de l’institution;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">Helvecura: les données concernant l’état actuel et l’état visé des stocks ainsi que les ventes des médicaments à usage humain répertoriés sur la Plateforme des produits thérapeutiques.</dd>
</dl>
<p class="absatz man-space-before-4"><sup>2</sup> Le bureau de notification ne peut accéder à ces données que s’il en a besoin pour accomplir son mandat légal, notamment pour effectuer les préparatifs et prendre les mesures d’intervention nécessaires.</p>
<div class="footnotes"><p id="fn-d7e345"><sup><a href="#fnbck-d7e345">3</a></sup><sup></sup> <a href="https://fedlex.data.admin.ch/eli/cc/2001/422" target="_blank">RS <b>812.21</b></a></p></div>
</div></article><article id="art_12"><a name="a12"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_12"><b>Art. 12</b> Durée de conservation des données</a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4">Les données saisies sur la Plateforme des produits thérapeutiques sont conservées pendant au moins dix ans à compter de leur saisie et sont détruites au plus tard quinze ans après leur saisie.</p></div></article><article id="art_13"><a name="a13"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_13"><b>Art. 13</b> Sécurité des données</a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4">Le domaine Produits thérapeutiques fixe, dans un règlement sur le traitement des données, des mesures organisationnelles et techniques permettant d’empêcher tout traitement illicite des données et de garantir une journalisation automatique du traitement des données.</p></div></article>
</div></section><section id="sec_5"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#sec_5">Section 5 Financement</a>
</h1>
<div class="collapseable"><article id="art_14"><a name="a14"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_14"><b>Art. 14</b></a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4">La Confédération finance le bureau de notification.</p></div></article></div></section><section id="sec_6"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#sec_6">Section 6 Dispositions finales</a>
</h1>
<div class="collapseable">
<article id="art_15"><a name="a15"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_15"><b>Art. 15</b> Exécution</a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4">Le domaine Produits thérapeutiques exécute la présente ordonnance.</p></div></article><article id="art_16"><a name="a16"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_16"><b>Art. 16</b> Modification de l’annexe</a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4">Le Département fédéral de l’économie, de la formation et de la recherche peut modifier l’annexe après consultation des cantons, des milieux économiques concernés et des établissements sanitaires.</p></div></article><article id="art_17"><a name="a17"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_17"><b>Art. 17</b><b></b> <b></b>Abrogation d’un autre acte</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4">L’ordonnance du 12 août 2015 sur le bureau de notification pour les médicaments vitaux à usage humain<sup><a href="#fn-d7e418" id="fnbck-d7e418">4</a></sup> est abrogée.</p>
<div class="footnotes"><p id="fn-d7e418"><sup><a href="#fnbck-d7e418">4</a></sup><sup></sup> [<a href="https://fedlex.data.admin.ch/eli/oc/2015/544" target="_blank">RO <b>2015</b> 2895</a>; <b></b><a href="https://fedlex.data.admin.ch/eli/oc/2017/313" target="_blank"><b>2017</b> 3179 </a>ch. I 1; <b></b><a href="https://fedlex.data.admin.ch/eli/oc/2021/132" target="_blank"><b>2021</b> 132 </a>annexe ch. 29; <b></b><a href="https://fedlex.data.admin.ch/eli/oc/2022/568" target="_blank"><b>2022 </b>568 </a>annexe 2 ch. II 67; <b></b><a href="https://fedlex.data.admin.ch/eli/oc/2023/735" target="_blank"><b>2023</b> 735 </a>annexe 2 ch. II 33, <a href="https://fedlex.data.admin.ch/eli/oc/2023/802" target="_blank">802</a>]</p></div>
</div></article><article id="art_18"><a name="a18"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_18"><b>Art. 18</b> Entrée en vigueur</a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4" msg:wcstyle02-4="loose pPr/keepLines" xmlns:msg="urn:com:c-moria:legi4ch:xslt:message">La présente ordonnance entre en vigueur le 1<sup>er</sup> juillet 2025.</p></div></article>
</div></section></main><div id="annex"><section id="annex_u1"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_u1">Annexe</a>
</h1>
<div class="collapseable">
<p class="titelanhtext">(art. 2, al. 1)</p>
<section id="annex_u1/lvl_u1"><h2 class="heading" role="heading" aria-level="2">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_u1/lvl_u1">Liste des principes actifs</a>
</h2>
<div class="collapseable">
<p></p>
<div class="table"><table border="1">
			
			
			<tr>
				
				
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Code ATC*</p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Principe actif</p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Remarque</p>
				</th>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A07A</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">anti-infectieux intestinaux</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A09AA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">enzymes multiples (lipase, protéase, etc.)</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A10A</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">insulines et analogues</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A11CC05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">cholécalciférol (vitamine D3)</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A11DA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">thiamine (vitamine B1)</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A11DB</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vitamine B1 en association avec vitamine B6 et/ou vitamine B12</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A11GA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">acide ascorbique (vitamine C)</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A11HA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">pyridoxine (vitamine B6)</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A11HA04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">riboflavine (vitamine B2)</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A12CC02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">sulfate de magnésium</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A12CE02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">sélénite de sodium</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AA04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">phenprocoumone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AA07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">acénocoumarol</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AB01 </p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">héparine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">&gt; 100 UI/ml</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">antithrombine III</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AB04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">daltéparine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AB05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">énoxaparine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AB06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">nadroparine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AB09</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">danaparoïde</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AD02 </p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">altéplase</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">dosage &gt; 2 mg</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AD04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">urokinase</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AD11</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ténectéplase</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AE03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">argatroban</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AE07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">dabigatran</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AF01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">rivaroxaban</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AF02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">apixaban</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AF03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">édoxaban</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AX05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">fondaparinux</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B02AA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">acide tranexamique</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B02BD</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">facteurs de coagulation</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05AA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">albumine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05BA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">acides aminés</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05BA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">émulsions lipidiques</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05BA03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">hydrates de carbone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales avec concentration de glucose ≥ 20 % w/v, volume &gt; 50 ml</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05BA10</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">solutions pour l’alimentation parentérale, associations</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">poches tricompartimentées pour la voie veineuse centrale</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05BB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">électrolytes</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05DB</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">solutions hypertoniques pour la dialyse péritonéale </p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05XA14</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">glycérophosphate de sodium</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05XA31</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">électrolytes, associations, y c. oligo-éléments purs</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05XB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">alanyl-glutamine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05XC</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vitamines</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05ZB</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">solutions pour hémofiltration</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">C01CA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">isoprénaline</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">C01CA03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">noradrénaline</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">C01CA07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">dobutamine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">C01CA24</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">adrénaline</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">C03CA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">furosémide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">C07AB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">métoprolol</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">C07AG01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">labétalol</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">D08AC52</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">chlorhexidine, associations</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">volume &gt; 100 ml</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">D08AG02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">povidone iodée</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">volume &gt; 100 ml</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">D08AJ57 </p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">octénidine, associations</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">D08AX05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">isopropanol</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">D08AX53</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">propanol, associations</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">G02AD05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">sulprostone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">H01AA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tétracosactide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">H01BA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">desmopressine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">H01BB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ocytocine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">H01BB03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">carbétocine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">antibiotiques à usage systémique</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">sauf J01Z</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">antifongiques à usage systémique</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J04A</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">antituberculeux</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J05AB06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ganciclovir</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J05AB14</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">valganciclovir</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J05AD01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">foscarnet</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J05AH02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">oseltamivir</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J06BA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">immunoglobulines humaines</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">non spécifiques, application extravasculaire</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J06BA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">immunoglobulines humaines</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">non spécifiques, application intravasculaire</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J06BB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">immunoglobuline anti-D</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J06BB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">immunoglobuline antitétanique</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J06BB03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">immunoglobuline anti-varicelle/zona</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J06BB04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">immunoglobuline anti-hépatite B</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J06BB05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">immunoglobuline antirabique</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vaccins</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">cyclophosphamide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AA03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">melphalan</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AA06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ifosfamide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AA09</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">bendamustine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">busulfan</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AC01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">thiotépa</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AD01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">carmustine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AX03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">témozolomide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AX04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">dacarbazine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">méthotrexate</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">mercaptopurine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BB03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tioguanine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BB04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">cladribine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BB05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">fludarabine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BB07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">nélarabine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BC01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">cytarabine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BC02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">fluorouracile</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BC05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">gemcitabine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BC06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">capécitabine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BC07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">azacitidine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01CA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vincristine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01CA04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vinorelbine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01CB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">étoposide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01CD01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">paclitaxel</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01CD02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">docétaxel</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01CD04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">cabazitaxel</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01CE02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">irinotécan</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ancien code ATC L01XX19</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01CX01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">trabectédine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01DB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">doxorubicine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01DB03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">épirubicine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01DC01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">bléomycine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01EA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">imatinib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01EB04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">osimertinib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01EC02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">dabrafénib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01EE01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tramétinib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01EH02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">nératinib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01EL01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ibrutinib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01EX04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vandétanib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01EX10</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">midostaurine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">rituximab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">inotuzumab ozogamicine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FC01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">daratumumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FD01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">trastuzumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FD02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">pertuzumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FD03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">trastuzumab emtansine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FE01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">cétuximab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FF02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">pembrolizumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FF03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">durvalumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FF05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">atézolizumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FG01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">bévacizumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FG02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ramucirumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FX02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">gemtuzumab ozogamicine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FX04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ipilimumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FX05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">brentuximab védotine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FX07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">blinatumomab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">cisplatine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">carboplatine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XA03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">oxaliplatine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XF01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">trétinoïne</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XG01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">bortézomib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XG02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">carfilzomib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XH03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">panobinostat</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XJ01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vismodégib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XX05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">hydroxycarbamide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XX23</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">mitotane</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XX24</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">pégaspargase</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XX27</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">trioxyde d’arsenic</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XX52</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vénétoclax</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L02AE03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">goséréline</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L02BA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tamoxifène</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L02BA03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">fulvestrant</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L03AX03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vaccin BCG</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L04AA04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">immunoglobuline anti-thymocytes (lapin)</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L04AA13</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">léflunomide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L04AB06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">golimumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L04AC02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">basiliximab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L04AX01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">azathioprine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes perorales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L04AX03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">méthotrexate</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes perorales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L04AX04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">lénalidomide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">M01AB05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">diclofénac</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">M01AB15</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">kétorolac</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">M01AE17</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">dexkétoprofène</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">M03AB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">suxaméthonium</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">M03AC04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">atracurium</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">M03AC09</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">rocuronium</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">M03AC11</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">cisatracurium</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">M03CA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">dantrolène</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01AB07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">desflurane</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01AF03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">thiopental</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01AH</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">anesthésiques opioïdes</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01AH06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">rémifentanil</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01AX03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">kétamine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01AX10</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">propofol</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01BB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">lidocaïne</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01BB03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">mépivacaïne</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01BB04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">prilocaïne</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">morphine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AA03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">hydromorphone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AA05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">oxycodone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AA08</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">dihydrocodéine </p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">sauf antitussifs</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AA55</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">oxycodone avec naloxone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">péthidine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AB03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">fentanyl</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AE01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">buprénorphine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AF02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">nalbuphine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AJ06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">codéine avec paracétamol</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AJ13</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tramadol avec paracétamol</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AX01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tilidine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AX02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tramadol</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AX06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tapentadol</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02BA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">acide acétylsalicylique, y c. acétylsalicylate de lysine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02BB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">métamizole sodique</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02BE01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">paracétamol</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N03AX18</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">lacosamide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N05BA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">diazépam</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales et gouttes</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N05BA06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">lorazépam</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N07BC02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">méthadone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N07BC05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">lévométhadone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">R03CC02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">salbutamol</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">formes parentérales</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">R03CC05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">hexoprénaline</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">S01AD03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">aciclovir</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">pommade ophtalmique</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">S01JA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">fluorescéine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">gouttes ophtalmiques</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V03AB14</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">protamine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V03AB35</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">sugammadex</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V03AE02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">sévélamer</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V03AE03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">carbonate de lanthane III</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V03AE05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">complexe d’oxyhydroxyde de fer III, de saccharose et d’amidon</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V03AE07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">acétate de calcium </p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V03AF03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">folinate de calcium (acide folinique)</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V08AA</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">produits de contraste hydrosolubles, à élimination rénale, de haute osmolarité</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V08AB</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">produits de contraste hydrosolubles, à élimination rénale, de basse osmolarité</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V08BA</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">produits de contraste barytés</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V08CA</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">produits de contraste paramagnétiques</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3">V08DA</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3">produits de contraste pour échographie</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td colspan="3"><dl class="man-space-after-0">
<dt class="man-space-after-3">* </dt>
<dd class="man-space-after-3">Les codes ATC (codes des principes actifs figurant dans le Anatomical Therapeutic Chemical Classification System) peuvent être consultés en anglais (version officielle) sur le site du Centre collaborateur de l’OMS pour la méthodologie sur les statistiques pharmaceutiques à l’adresse suivante: <a href="https://www.whocc.no/atc_ddd_index/" target="_blank">
							www.whocc.no 
						</a>&gt; ATC/DDD Index. La répartition des produits reflète les codes ATC attribués par l’Institut suisse des produits thérapeutiques.</dd>
</dl></td>
			</tr>
		</table></div>
<p class="abstand1seite man-space-before-0"></p>
</div></section>
</div></section></div>
</div></body>
</html>
